Fruquintinib - Latest Advances

Safety of fruquintinib mono- and combo therapy in metastatic colorectal cancer: real-world subgroup analysis from China.

Journal: Future oncology (London, England)

Published: May 28, 2026

FRUQUITAS trial: Study design of an ENGIC intergroup randomized phase III of trifluridine/tipiracil +/- fruquintinib in pre-treated metastatic gastro-oesophageal adenocarcinoma.

Journal: Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver

Published: April 03, 2026

Expert opinion on treatment patterns in metastatic colorectal cancer management in Eastern Europe.

Journal: BMC proceedings

Published: March 23, 2026

Fruquintinib in combination with tislelizumab versus trifluridine/tipiracil and bevacizumab in third-line and beyond MSS mCRC without active liver metastases-the IKF-080/AIO-QUINTIS trial.

Journal: ESMO gastrointestinal oncology

Published: March 19, 2026

CTMP-REV7 axis modulates MHC-I antigen presentation via CDK1-AKT crosstalk in MSI-L/MSS colorectal cancer.

Journal: Cellular oncology (Dordrecht, Netherlands)

Published: March 18, 2026

Fruquintinib or Regorafenib? A Weighted Toxicity Score Analysis to Facilitate Better Discussions on Toxicity and Benefits in Later-line Colorectal Cancer Treatment.

Journal: Clinical colorectal cancer

Published: March 18, 2026

Metastatic Colorectal Cancer Beyond Third-Line Treatment: Systematic Review and Meta-Analysis of Later-Line Therapies.

Journal: Journal of clinical medicine

Published: March 10, 2026

A Multifunctional Calcium Phosphate Nanoplatform Inducing Synergistic Copper/Calcium Overload and Antiangiogenesis for Enhanced Cancer Therapy.

Journal: ACS nano

Published: March 07, 2026

Multikinase inhibitors in refractory metastatic colorectal cancer: an optimal sequence?

Journal: Clinical advances in hematology & oncology : H&O

Published: February 20, 2026

Analysis of fruquintinib in patients with metastatic colorectal cancer who were enrolled in Spain: results from the global FRESCO-2 study.

Journal: ESMO gastrointestinal oncology

Published: February 06, 2026

Managing adverse events in patients with metastatic colorectal cancer receiving trifluridine/tipiracil in combination with bevacizumab.

Journal: ESMO gastrointestinal oncology

Published: February 06, 2026

Possible Fruquintinib Associated Ischemic Colitis in a Patient with Metastatic Ampullary Adenocarcinoma.

Journal: European journal of case reports in internal medicine

Published: January 26, 2026